Neurocrine Biosciences: Schizophrenia trials

The registry lists 18 Schizophrenia studies with Neurocrine Biosciences as lead sponsor. 6 are open to participants now and 8 have results posted.

Phase 1 2Phase 2 8Phase 3 6Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of NBI-1117570 in Inpatient Adults With SchizophreniaRecruitingNCT07288333Phase 2
• Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaRecruitingNCT07227818Phase 3
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaRecruitingNCT07114874Phase 3
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingNCT07105111Phase 4
• NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaRecruitingNCT07105098Phase 3
• NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaRecruitingNCT06963034Phase 3
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedNCT05859698Phase 4Results posted
• A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of SchizophreniaCompletedNCT03382639Phase 2Results posted
• A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With SchizophreniaCompletedNCT03359785Phase 2Results posted
• A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable SchizophreniaCompletedNCT03319953Phase 2Results posted
• Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics StudyCompletedNCT02748694Phase 1Results posted
• A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy ParticipantsTerminatedNCT02566759Phase 1Results posted
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)CompletedNCT01688037Phase 2Results posted
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT01393600Phase 2Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for SchizophreniaTerminatedNCT05654870Phase 3
• Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With SchizophreniaCompletedNCT05545111Phase 2
• Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With SchizophreniaTerminatedNCT05182476Phase 2
• Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaCompletedNCT05110157Phase 3